CAP ’13 – THE Pathologists’ Meeting – October 13 – 16, 2013™
HomeVirtual CatalogLearningSpecial EventsConnection Café & ExhibitsGeneral InfoTravel & HotelExhibitors
Learning

Courses by Topic


Courses by Day


Faculty Index

AP109  Molecular Testing Guidelines for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Monday, October 14
8:00–10:00 AM
2.0 CME CREDITS

Patient Care System Based Practice

The treatment of adenocarcinoma of the lung has been transformed by the discovery of critical oncogene mutations associated with response to targeted antitumor therapies, most notably EGFR mutation as an indicator of response to erlotinib and ALK rearrangement as an indicator of response to crizotinib. These discoveries have spurred a growing demand for high-quality molecular diagnostic testing of these tumors for patient management and monitoring. This course will present evidence-based professional guidelines for the selection of patients, samples, methodology, and validation strategies that were developed jointly by experts from three organizations: the Association for Molecular Pathology (AMP), the College of American Pathologists (CAP), and the International Association for the Study of Lung Cancer (IASLC).

You will learn to:

Faculty
Marc Ladanyi, MD, FCAP
Neal I. Lindeman, MD, FCAP

 

Cosponsored by Pulmonary Pathology Society and Association for Molecular Pathology Pulmonary Pathology Society and Association for Molecular Pathology

This course will be streamed live during CAP ’13. Learn more about how to participate. Please note that CME will not be offered for viewing a session via live streaming.

 

 

 

 

Register Now Course Materials